Diversity of resistant and susceptible isolates.

Slides:

Advertisements

Similar presentations

Drug-Resistant Tuberculosis

Advertisements

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.

TREATMENT OF TUBERCULOSIS, 2003

Tuberculosis Evaluation in the Underserved Community John W. Wilson, MD Division of Infectious Diseases Mayo Clinic, Rochester.

Page 1 CPTR Workshop, Oct TB Drug Co-Development Roundtable Perspective from Bayer Dr. Martin Springsklee MD Head Global Medical Affairs Therapy.

Occupational MDR-TB & me Reaching Zero TB Deaths and Zero New TB Infections Satellite Symposium, Kuala Lumpur, Malaysia Dalene and Arne von Delft13 November.

Adverse Drug Reactions to Anti-TB drugs Dr M A Jalil Chowdhury Professor of Medicine Bangabandhu Sheikh Mujib Medical University.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.

Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.

MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant

Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Guidelines for chemotherapy of tuberculosis in Taiwan 馬偕紀念醫院一般內科及感染科主治醫師曾祥洸

Hepatotoxicity. Overview INH, Rifampin, and PZA all are associated with DILI (drug-induced liver injury) Only one case of DILI has been reported for Ethambutol.

Tuberculosis: What you need to know!

Page 1 Extreme Drug Resistant TB and the Work Place Dr Jennifer Coetzee Ampath.

Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences.

HAIVN Harvard Medical School AIDS Initiative in Vietnam

British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.

Introduction to the Forms Julie Tomaro, BSN Washington State Department of Health INTERJURISDICTIONAL TB NOTIFICATION (IJN) TRANSFER AND FOLLOW-UP FORMS.

Surveillance on drug resistance in tuberculosis C N Paramasivan Tuberculosis Research centre (ICMR)

TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.

Animal Efficacy Studies for Antitubercular Agents V. Balasubramanian ASTRAZENECA R&D BANGALORE, INDIA.

Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.

Molecular diagnosis of drug resistant tuberculosis by a DNA array

Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.

Anti-tuberculosis drugs. First-line drugs Isoniazid (INH or H) Rifampin (RMP or R) Ethambutol (EMB or E) Pyrazinamide (PZA or Z)

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Ward 5D Linda Iskandar 1. Patient MR From Nepal, has been in Australia for 2 years on a dependent student visa studying nursing. Presenting complaints.

항결핵제 감수성시험의 정도관리 2009 년 7 월 3 일 결핵연구원 김창기. 배경 Emergence of resistant tuberculosis –Multidrug-resistant tuberculosis (MDR-TB) Resistant to INH and RIF.

Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.

Anti-TB Agents Dr. Jeff Hobden MIP. Mycobacterium tuberculosis TB is hard to kill with antibiotics TB is hard to kill with antibiotics Slow growth Slow.

Tuberculosis. TB is a common infectious disease caused by the bacterium Mycobacterium tuberculosis. The bacteria usually affects the lungs but it can.

Drug Resistant Tuberculosis

Treatment for Multi-drug Resistant TB

Dose and range (mg/kg body weight)

Treatment of TB Disease

Treatment algorithm for tuberculosis

Antimycobacterial drugs

CHM 708 Anti-Bacterial Drugs.

Treatment of Latent TB Infection (LTBI)

SUSCEPTIBILITY TESTING OF MYCOBACTERIUM KANSASII STRAINS ISOLATED FROM PATIENTS BETWEEN 2000 AND 2015 IN POLAND Zofia Bakuła1, Magdalena Modrzejewska1,

Treatment algorithm for tuberculosis

1 Drug susceptible TB Limited resistance MDR-TB (Frieden, 1993) XDR-TB

Drug Resistant (DR) TB (Back to Basics)

Ph.D, FMLSCN, FIBMS (Lond)

Laboratory Testing for Tuberculosis

TABLE 2: Beijing strains assayed in THP-1 cells

Drug resistant tuberculosis

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

HSP65-PRA identification of non-tuberculosis mycobacteria from 4892 samples suspicious for mycobacterial infections M. Saifi, E. Jabbarzadeh, A.R. Bahrmand,

L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Clinical Epidemiology and Global Health

Gene-wise Tajima’s D values and gene lengths.

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

CASE HOLDING FOR PMDT.

Treatment of Drug Resistant TB - Questions

Genomic phylogeny reveals the long-term coexistence of diverse clades.

DR SAUMU WAYUWA KPA ANNUAL SCIENTIFIC CONFERENCE 2019

Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;

Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.

Recombinant phenotyping.

Prediction of cross-resistance among rifampin-resistant isolates.

Presentation transcript:

Diversity of resistant and susceptible isolates. Diversity of resistant and susceptible isolates. (A) Counts of genes with no nucleotide diversity in resistant and susceptible subpopulations. (B) Gene-wise nucleotide diversity (excluding invariant genes) in susceptible and resistant isolates. Among genes in which nucleotide diversity is measurable, it is similar between resistant and susceptible isolates even when drug resistance-associated genes and targets of independent mutation identified by Farhat et al. (24) are removed (P = 0.13). Abbreviations: AMI, amikacin; CAP, capreomycin; EMB, ethambutol; ETO, ethionamide; INH, isoniazid; KAN, kanamycin; MOX, moxifloxacin; OFL, ofloxacin; PRO, prothionamide; PZA, pyrazinamide; RIF, rifampin; STR, streptomycin. Tatum D. Mortimer et al. mSystems 2018; doi:10.1128/mSystems.00108-17